Abstract 46P
Background
As a consequence of the German National Cancer Plan, cancer centres have been established in each region of the country. Lung cancer centres are responsible for coordinating the care of lung cancer patients in each region and to diagnose and treat them according to the latest evidence-based knowledge. For this purpose, every patient should be reviewed by a multidisciplinary tumour board. In the tumour board, an individual treatment plan is discussed, and treatment recommendations are given. We investigated: 1.) adherence to the recommendations from tumour boards; 2.) which factors determine the adherence to tumour board recommendations and 3.) what is the relationship between the adherence to tumour board recommendations and patient outcomes in terms of overall survival (OS).
Methods
Data from 1784 newly-diagnosed patients with lung cancer discussed in tumour boards in one certified lung cancer centre in Northern Germany between 2014 and 2018 were documented and evaluated according to the adherence to tumour board recommendations. A preliminary analysis of the first 161 cases is presented. Data was analysed descriptively.
Results
Median age of the 161 patients was 66 years (36-88 yrs) and 58% (n=94/161) of them were male. Most of the patients had an ECOG status of 0/1 (73%; n=118/161) and 84% of them were current/ex heavy smokers (n=135/161). 67% (n=108/161) of the patients that were discussed in the tumour board subsequently received treatment at the same lung cancer centre. Treatment recommendations from the tumour boards were completely adhered to in 78% (n=125/161) of patients. There were different reasons for non-adherence, e.g. patient’s wish, patient characteristics and death before starting therapy. Median OS for the 161 patients was 15 months. Patients with complete adherence to the tumour board recommendation had an OS of 15 months (n=127) compared to 5 months (n=17) for patients with a partial adherence compared to 1 month (n=17) for patients with a non-adherent treatment (P<0.000).
Conclusions
Preliminary results suggests that patients whose treatments adhere to recommendations from a multidisciplinary tumour board after first diagnosis had a longer OS than patients with received other therapy. More cases will be presented at the meeting using a multivariate analysis which includes patient characteristics and healthcare organizations that took over further treatment as predictors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Carl-v-Ossietzky University of Oldenburg.
Funding
Has not received any funding.
Disclosure
J. Roeper: Honoraria (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca; Honoraria (self): Roche. F. Griesinger: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Celgene; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Lilly; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Takeda; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Siemens; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AbbVie. All other authors have declared no conflicts of interest.